Francois-Clement Bidard

基本信息

浏览量：155

职业迁徙

个人简介

His clinical work primarily focuses on breast cancers. His research aims at characterizing the cellular mechanisms involved in the metastatic process, with a focus on blood biomarkers (circulating tumor cells, circulating tumor DNA etc.).

研究兴趣

论文共 473 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Abstract PS17-02: Elacestrant Vs Standard-of-care in ER+/HER2- Advanced or Metastatic Breast Cancer (mbc) with ESR1 Mutation: Key Biomarkers and Clinical Subgroup Analyses from the Phase 3 EMERALD Trial

Aditya Bardia,Joyce O'Shaughnessy,Francois-Clement Bidard,Patrick Neven,José Ángel García-Sáenz,Philippe Aftimos,Javier Cortés,Janice Lu,Giulia Tonini,Kathy Puvana Theall, Alessandro Paoli,Virginia Kaklamani

Cancer Researchno. 9_Supplement (2024): PS17-02

引用0浏览0引用

Circulating Tumor Cells in Breast Cancer: Clinical Validity and Utility

Thibault Thomas-Bonafos, Jean Yves Pierga,François-Clément Bidard,Luc Cabel, Nicolas Kiavue

NPJ breast cancerno. 1 (2024): 103-103

引用0浏览0WOSNATURE引用

Elacestrant in ESR1-mutant, Endocrine-Responsive Metastatic Breast Cancer: Should Health Authorities Consider Post Hoc Data to Inform Priority Access

C. Valenza,D. Trapani,F. -c. Bidard,J. Gligorov,J. Cortes,N. Turner, F. Dalenc,F. Penault-Llorca, G. Freyer,M. Arnedos, C. Villanueva,S. Loibl,B. Pistilli, G. Curigliano

ESMO Open（2024）

引用0浏览0WOS引用

International phase 3 clinical trial evaluating PF-07220060 plus fulvestrant in patients with HR+/HER2− advanced/metastatic breast cancer with progression after a prior CDK4/6 inhibitor

Antonio Giordano,Michail Ignatiadis,Carlos H. Barrios,Francois Clement Bidard,Binghe Xu, Alicia M Vana,Jason Gong,Ariadna Holynskyj,Prashanth Gopalakrishna,Hope S. Rugo

Journal of Clinical Oncologyno. 16_suppl (2024)

引用0浏览0引用

International Phase 3 Clinical Trial Evaluating PF-07220060 Plus Fulvestrant in Patients with HR+/HER22 Advanced/metastatic Breast Cancer with Progression after a Prior CDK4/6 Inhibitor

Antonio Giordano,Michail Ignatiadis,Carlos H. Barrios,Francois Clement Bidard,Binghe Xu, Alicia M. Vana,Jason Gong,Ariadna Holynskyj,Prashanth Gopalakrishna,Hope S. Rugo

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

引用0浏览0引用

ESR1 Mutations Emerging During Neoadjuvant Endocrine Therapy in Postmenopausal ER+/HER2-early Breast Cancer Patients: Prevalence and Prognostic Impact

Jose Luis Sandoval,Helene Salaun,Shufang Renault,Marcela Carausu,Aurore Rampanou,Caroline Hego,Matthieu Carton,Luc Cabel,Jean-Yves Pierga,Romain Geiss,Francois-Clement Bidard, Florence Lerebours

CANCER RESEARCHno. 9 (2024)

引用0浏览0引用

ECLECTIC: 18 F-fluoroestradiol PET and Circulating Biomarkers to Guide the Choice of the Second Line Therapy for ER+, HER2- Metastatic Breast Cancer: A Phase 3 Trial

Francois Clement Bidard,Audrey Bellesoeur,Nawale Hajjaji,Elise Rowinski,Alexandre De Nonneville,Marie Alexandre, Paul Lalire,Antoine Deleuze,Catherine Alix-Panabieres, Isabelle Turbiez,Frederique Berger,Romain-David Seban

JOURNAL OF CLINICAL ONCOLOGY（2024）

引用0浏览0引用

Abstract PO3-04-13: SUMIT-ELA: Phase 1b/2 Combination of Cyclin-Dependent Kinase 7 Inhibitor (cdk7i) Samuraciclib and Selective Estrogen Receptor Degrader (SERD) Elacestrant in Advanced Hormone Receptor Positive (HR+) Breast Cancer after CDK4/6i

Amita Patnaik,Silvia Antolín,Meritxell Bellet Ezquerra,François‐Clément Bidard,Valentina Boni, Maxime Brunet, Mario Campone, Carlos A. Garay,Raquel Gómez Bravo,Sacha J. Howell,Rinath Jeselsohn,Simon Lord, Paolo Mazzei,Maria J. de Miguel,Erin Roesch,Agostina Stradella,Hélène Vanacker,Cécile Vicier,Seth A. Wander, Glen Clack,Stuart McIntosh

Cancer Researchno. 9_Supplement (2024): PO3-13

引用0浏览0引用

238MO PROMENADE: PembROlizuMab for Early Triple Negative ER-low Breast Cancer, Real World French Cohort

F. Cherifi,L. Cabel,C. Bousrih, E. Volant, F. Dalenc,B. Mery, M. Auvray Kuentz, M. Alexandre, L. Benistant,M. Leheurteur,C. Bailleux, M. Debled, J-S. Frenel,D. Loirat,F.C. Bidard, S. Aho, A. Glenet, J.T.L. Ribeiro Mourato,F. Christy,G. Emile

Annals of Oncology (2024)

引用0浏览0引用

Efficacy of Administration Sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low Metastatic Breast Cancer

F. Poumeaud, M. Morisseau,L. Cabel,A. Goncalves, C. Rivier,O. Tredan, E. Volant,J. -s. Frenel,S. Ladoire,W. Jacot,M. Jamelot, H. Foka Tichoue,A. Patsouris,L. Teixeira,F. -c. Bidard,D. Loirat, M. Brunet,C. Levy,C. Bailleux,B. Cabarrou,A. Deleuze,L. Uwer,E. Deluche,T. Grellety, C. Franchet, F. Fiteni, H. Bischoff, R. Vion,M. Pagliuca,B. Verret,S. Becourt, T. Reverdy,A. de Nonneville,F. Dalenc

BRITISH JOURNAL OF CANCERno. 4 (2024): 702-708

引用0浏览0WOSNATURE引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn

教授

论文共 473 篇作者统计合作学者相似作者